Surgical management of bladder cancer in 2003

Expert Review of Anticancer Therapy

Volumn 3, Issue 6, 2003, Pages 781-792

  Wade, Merle ^a   Seigne, John D ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Bladder neoplasm; Lymphadenectomy; Radical cystectomy; Surgery; Transurethral resection; Urethrectomy

Indexed keywords

ANTINEOPLASTIC AGENT;

BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CYSTECTOMY; ENDOSCOPIC SURGERY; HIGH RISK PATIENT; HUMAN; LAPAROSCOPIC SURGERY; LYMPHADENECTOMY; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; SAFETY; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

EID: 0347589399     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.6.781     Document Type: Review

References (73)

1. Herr HW, Donat SM, Dalbagni G. Correlation of cystoscopy with histology of recurrent papillary tumors of the bladder. J. Urol. 168(3), 978-980 (2002).
2. Kiemeney LA, Witjes JA, Heijbroek RP, Koper NP, Verbeek AL, Debruyne FM. Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Members of the Dutch South-East Co-Operative Urological Group. Br. J. Urol. 73(2), 164-171 (1994).
3. Althausen AF, Prout GR Jr, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J. Urol. 116(5), 575-580 (1976).
4. Donat SM, Wei DC, McGuire MS, Herr HW. The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer. J. Urol. 165(5), 1580-1584 (2001).
5. Tolley DA, Parmar MK, Grigor KM et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J. Urol. 155(4), 1233-1238 (1996).
6. Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J. Urol. 161(4), 1120-1123 (1999).
7. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin bladder cancer. N. Engl. J. Med. 326(11), 737-740 (1992).
8. Shipley WU, Kaufman DS, Zehr E et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 60(1), 62-67 (2002).
9. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349(9), 859-866 (2003).
10. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am. J. Surg. Pathol. 22(12), 1435-1448 (1998).
11. Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J. Urol. 163(1), 60-61 (2000).
12. Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J. Urol. 170(2 Pt 1), 433-437 (2003).
13. Herr HW. Routine CT scan in cystectomy patients: does it change management? Urology 47(3), 324--325 (1996).
14. MacVicar AD. Bladder cancer staging. BJU Int, 86(Suppl. 1), 111-122 (2000).
15. Syed HA, Biyani CS, Bryan N, Brough SJ, Powell CS. Holmium: YAG laser treatment of recurrent superficial bladder carcinoma: initial clinical experience. J. Endourol. 15(6), 625-627 (2001).
16. Elliott DS, Segura JW, Lightner D, Patterson DE, Blute ML. Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney. Urology 58(2), 174-178 (2001).
17. Koenig F, McGovern FJ, Enquist H, Larne F, Deutsch TF, Schomacker KT. Autofluorescence guided biopsy for the early diagnosis of bladder carcinoma. J. Urol. 159(6), 1871-1875 (1998).
18. Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J. Urol. 135(5), 920-922 (1986).
19. Heney NM. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol. Clin. North Am. 19(3), 429-433 (1992).
20. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163(4), 1124-1129 (2000).
21. Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J. Clin. Oncol. 19(1), 89-93 (2001).
22. Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J. Urol. 167(4), 1573-1583 (2002).
23. Dandekar NP, Tongaonkar HB, Dalal AV, Kulkarni JN, Kamat MR. Partial cystectomy for invasive bladder cancer. J. Surg. Oncol. 60(1), 24-29 (1995).
24. Herr HW, Scher HI. Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J. Clin. Oncol. 12(5), 975-980 (1994).
25. Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 4(5), 473-485 (1983).
26. Walsh PC, Schlegel PN. Radical pelvic surgery with preservation of sexual function. Ann. Surg. 208(4), 391-400 (1988).
27. Madersbacher S, Studer UE. Contemporary cystectomy and urinary diversion. World J. Urol. 20(3), 151-157 (2002).
28. Vallancien G, Abou El Fettouh H, Cathelineau X, Baumert H, Fromont G, Guillonneau B. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J. Urol. 168(6), 2413-2417 (2002).
29. Chang SS, Cole E, Smith JA Jr, Cookson MS. Pathological findings of gynecologic organs obtained at female radical cystectomy. J. Urol. 168(1), 147-149 (2002).
30. Millikan R, Dinney C, Swanson D et al, Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J. Clin. Oncol. 19(20), 4005-4013 (2001).
31. Herr HW, Donat SM. Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J. Urol. 165(1), 62-64 (2001).
32. Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J. Urol. 165(3), 811-814 (2001).
33. Rodel C, Grabenbauer GG, Kuhn R et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J. Clin. Oncol. 20(14), 3061-3071 (2002).
34. Hussain SA, James ND. Organ preservation strategies in bladder cancer. Expert Rev. Anticancer Ther. 2(6), 641-651 (2002).
35. Clayman RV, Kavoussi LR, Soper NJ et al. Laparoscopic nephrectomy: initial case report. J. Urol. 146(2), 278-282 (1991).
36. Menon M, Tewari A. Robotic radical prostatectomy and the Vattikuti Urology Institute technique: an interim analysis of results and technical points. Urology 61(4 Suppl. 1), 15-20 (2003).
37. Gill IS, Kaouk JH, Meraney AM et al. Laparoscopic radical cystectomy and continent orthotopic ileal neobladder performed completely intracorporeally: the initial experience. J. Urol. 168(1), 13-18 (2002).
38. Peterson AC, Lance RS, Ahuja S. Laparoscopic hand assisted radical cystectomy with ileal conduit urinary diversion. J. Urol. 168(5), 2103-2105 (2002).
39. Morreira S, Pow-Sang J, Helal M, Lockhart J. Cutaneous Urostomy. Southeastern AUA meeting, Savannah, GA, USA (2003).
40. Bochner BH, Herr HW, Reuter VE. Impact of separate versus en bloc pelvic lymph node dissection on the number of lymph nodes retrieved in cystectomy specimens. J. Urol. 166(6), 2295-2296 (2001).
41. Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J. Urol. 167(3), 1295-1298 (2002).
42. Stein JP, Cai J, Groshen S, Skinner DG. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en bloc pelvic lymphadenectomy: concept of lymph node density. J. Urol. 170(1), 35-41 (2003).
43. Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J. Urol. 169(3), 943-945 (2003).
44. Lerner SP, Skinner DG, Lieskovsky G et al. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J. Urol. 149(4), 758-764 (1993).
45. Lebret T, Herve JM, Yonneau L et al. After cystectomy, is it justified to perform a bladder replacement for patients with lymph node positive bladder cancer? Eur. Urol. 42(4), 344-349 (2002).
46. Nixon RG, Chang SS, Lafleur BJ, Smith JA, Cookson MS. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J. Urol. 167 (2 Pt 1), 502-505 (2002).
47. Freeman JA, Esrig D, Stein JP, Skinner DG. Management of the patient with bladder cancer. Urethral recurrence. Urol. Clin. North Am. 21(4), 645-651 (1994).
48. Freeman JA, Tarter TA, Esrig D et al. Urethral recurrence in patients with orthotopic ileal neobladders. J. Urol. 156(5), 1615-1619 (1996).
49. Lin DW, Herr HW, Dalbagni G. Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy. J. Urol. 169(3), 961-963 (2003).
50. Chen ME, Pisters LL, Malpica A, Pettaway CA, Dinney CP. Risk of urethral, vaginal and cervical involvement in patients undergoing radical cystectomy for bladder cancer. results of a contemporary cystectomy series from M. D. Anderson Cancer Center. J. Urol. 157(6), 2120-2123 (1997).
51. Stein JP, Esrig D, Freeman JA et al. Prospective pathologic analysis of female cystectomy specimens: risk factors for orthotopic diversion in women. Urology 51(6), 951-955 (1998).
52. Lippert MC, Theodorescu D. The Hautmann neobladder with a chimney: a versatile modification. J. Urol. 158(4), 1510-1512 (1997).
53. Hollowell CM, Christiano AP, Steinberg GD. Technique of Hautmann ileal neobladder with chimney modification: interim results in 50 patients. J. Urol. 163 (1), 47-50 (2000).
54. Silver DA, Stroumbakis N, Russo P, Fair WR, Herr HW. Ureteral carcinoma in situ at radical cystectomy: does the margin matter? J. Urol 158(3 Pt 1), 768-771 (1997).
55. Schoenberg MP, Carter HB, Epstein JI. Ureteral frozen section analysis during cystectomy: a reassessment. J. Urol. 155(4), 1218-1220 (1996).
56. Stockle M, Meyenburg W, Wellek S et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J. Urol. 153(1), 47-52 (1995).
57. Taylor R, Rowland R, Turner WH. Urinary Diversion and Reconstruction. In: Comprehensive Textbook of Genitourinary Oncology (2nd Edition). Vogelzhang N, Scardino P, Coffey D (Eds), Lippincott, Williams & Wilkins, PA, USA, 448-472 (2000).
58. Seigne J, Lockhart JL. Choosing a continent urinary diversion. Contemp. Urol. 11, 19-32 (1999).
59. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19(3), 666-675 (2001).
60. Dalbagni G, Genega E, Hashibe M et al. Cystectomy for bladder cancer: a contemporary series. J. Urol. 165(4), 1111-1116 (2001).
61. Cheng L, Weaver AL, Leibovich BC et al. Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer 88(10), 2326-2332 (2000).
62. Skinner DG, Daniels JR, Russell CA et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J. Urol. 145(3), 459-464 (1991).
63. Segal R, Winquist E, Lukka H et al. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline. Can. J. Urol. 9(5), 1625-1633 (2002).
64. Koch MO, Coussens DM. Retrospective analysis of outcome in patients with nodal metastases from transitional cell carcinoma of lower urinary tract. Urology 43(3), 317-323 (1994).
65. Cookson MS, Chang SS, Wells N, Parekh DJ, Smith JA Jr. Complications of radical cystectomy for nonmuscle invasive disease: comparison with muscle invasive disease. J. Urol. 169(1), 101-104 (2003).
66. Game X, Soulie M, Seguin P et al. Radical cystectomy in patients older than 75 years: assessment of morbidity and mortality. Eur. Urol. 39(5), 525-529 (2001).
67. Soulie M, Straub M, Game X et al. A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J. Urol. 167(3), 1325-1328 (2002).
68. Birkmeyer JD, Siewers AE, Finlayson EV et al. Hospital volume and surgical mortality in the United States. N. Engl. J. Med 346(15), 1128-1137 (2002).
69. Chang SS, Cookson MS, Hassan JM, Wells N, Smith JA Jr. Routine postoperative intensive care monitoring is not necessary after radical cystectomy. J. Urol. 167(3), 1321-1324 (2002).
70. Singh R, Smeeton N, O'Brien TS. Identifying under-performing surgeons. BJU Int. 91(9), 780-784 (2003).
71. Madersbacher S, Hochreiter W, Burkhard F et al. Radical cystectomy for bladder cancer today: a homogeneous series without neoadjuvant therapy. J. Clin. Oncol. 21(4), 690-696 (2003).
72. Bassi P. Outcome of radical cystectomy for invasive bladder cancer. Curr. Opin. Urol. 10(5), 459-463 (2000).
73. Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Attar IA, Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J. Urol. 158(2), 393-399 (1997).